Buscar
03/10/2021
Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients
Riera, P, Paez, D. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. Expert Opinion on Drug Metabolism & Toxicology. 2021; 17(10)DOI:10.1080/17425255.2021.1974397. PMID:34486919. IF:4.936(Q1/3D).
01/10/2021
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC
Herbst, RS, Garon, EB, Kim, DW, Cho, BC, Gervais, R, Perez-Gracia, JL, Han, JY, Majem, M, Forster, MD, Monnet, I, Novello, S, Gubens, MA, Boyer, M, Su, WC, Samkari, A, Jensen, EH, Kobie, J, Piperdi, B, Baas, P. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. Research in Social & Administrative Pharmacy. 2021; 16(10)DOI:10.1016/j.jtho.2021.05.001. PMID:34048946. IF:3.348(Q2/5D).
01/10/2021
Electronic health records and patient registries in medical oncology departments in Spain
Ribelles, N, Alvarez-Lopez, I, Arcusa, A, Chacon, JI, de la Haba, J, Garcia-Corbacho, J, Garcia-Mata, J, Jara, C, Jerez, JM, Lazaro-Quintela, M, Leon-Mateos, L, Ramirez-Merino, N, Tibau, A, Garcia-Palomo, A. Electronic health records and patient registries in medical oncology departments in Spain. Clinical & Translational Oncology. 2021; 23(10)DOI:10.1007/s12094-021-02614-9. PMID:33864619. IF:3.340(Q3/7D).
01/10/2021
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
Riudavets, M, Sullivan, I, Abdayem, P, Planchard, D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021; 6(5)DOI:10.1016/j.esmoop.2021.100260. PMID:34479034. IF:6.883(Q1/3D).
01/09/2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Blackhall, F, Jao, K, Greillier, L, Cho, BC, Penkov, K, Reguart, N, Majem, M, Nackaerts, K, Syrigos, K, Hansen, K, Schuette, W, Cetnar, J, Cappuzzo, F, Okamoto, I, Erman, M, Langer, SW, Kato, T, Groen, H, Sun, ZW, Luo, Y, Tanwani, P, Caffrey, L, Komarnitsky, P, Reinmuth, N. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology. 2021; 16(9)DOI:10.1016/j.jtho.2021.02.009. PMID:33607312. IF:20.121(Q1/1D).
01/09/2021
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Garrido, P, Paz-Ares, L, Majem, M, Moran, T, Trigo, JM, Bosch-Barrera, J, Garcia-Campelo, R, Gonzalez-Larriba, JL, Sanchez-Torres, JM, Isla, D, Vinolas, N, Camps, C, Insa, A, Juan, O, Massuti, B, Paredes, A, Artal, A, Lopez-Brea, M, Palacios, J, Felip, E. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 2021; 10(17)DOI:10.1002/cam4.4135. PMID:34296539. IF:4.711(Q2/5D).